Sunday, Nov 19 2017 | Time 08:46 Hrs(IST)
image
  • Srinagar-Leh highway, Mughal road remain closed for 3rd day
  • Hiring prospects to remain subdued in short term:ASSOCHAM
  • Rail service remain suspended in Kashmir for security reasons
  • Honour killing: Man strangulates daughter to death, informs police
  • Honour killing: Man strangulates daughter to death, informs police
  • Argentina says satellite calls detected, likely from missing submarine
  • U'S' nuclear general says would resist 'illegal' Trump strike order
  • Lebanese FM may not attend Arab League meeting, to decide Sunday-senior Lebanese official
  • Strong winds and waves hinder search for Argentine submarine
  • Gerry Adams to step down in end of an era for Irish nationalism
  • Zimbabwe's ruling party set to sack Mugabe, sources say
  • Pogba returns to lead United past Newcastle
  • Roma win first post-Totti derby
  • Lebanese FM may not attend Arab League meeting, to decide Sunday-senior Lebanese official
  • Egyptian activists detained by court for protesting Red Sea islands transfer
Science & Technology Share

Circassia gives up on allergy after house dust mite study fails"

Circassia gives up on allergy after house dust mite study fails"

LONDON, Apr 18 (Reuters) Britain's Circassia Pharmaceuticals is throwing in the towel on allergy investment after a second high-profile clinical trial flop, focusing instead on building a broader respiratory business.
The failure of the company's immunotherapy to perform better than placebo in fighting dust mite allergy in a Phase IIb test follows similar negative results in a Phase III trial against cat allergy last year.
The company's stock lost two-third's of its value in a single session on the June 2016 cat results, which many investors feared undermined the allergy thesis, and the reaction on Tuesday was more muted, with shares losing around 3 percent.
In both cases, the company said, the immunotherapy failed because of a marked placebo effect among patients not on therapy.
The top shareholders in Circassia, which listed on the London stock market in March 2014 in Britain's largest biotech flotation for decades, are Invesco and Neil Woodford's investment management company, both big backers of UK science.
Woodford suffered another setback earlier this month when Allied Minds, which commercialises ideas from universities, announced a large writedown.
Circassia Chief Executive Steve Harris said he was "naturally disappointed" by the dust mite study failure.
"We remain convinced that the technology has biologic activity, but we also believe the difficulty in overcoming the placebo effect using the field study designs required by regulators represents a significant hurdle, and consequently we will make no further investment in our allergy portfolio," he said.
Instead, Circassia will concentrate on its wider respiratory business, in particular a new U.
S.
commercial collaboration with AstraZeneca.
Circassia last month secured U.
S.
rights from AstraZeneca for two drugs to treat chronic obstructive pulmonary disease for up to $230 million.
REUTERS RJ

Cipla

Cipla Receives Final Approval for Generic Pulmicort Respules

Mumbai, Nov 17(UNI) Pharma major, Cipla Ltd, today said that it
has received final approval for its Abbreviated New Drug Application
(ANDA) for Budesonide Inhalation Suspension, 0.

Antibiotic

Antibiotic resistance is one of the biggest threats to global health

Kolkata, Nov 14 (UNI) Antibiotic resistance is one of the biggest threats to global health, food security and development today.

Drop

Drop in cases of plague in Madagascar: WHO

Geneva, Nov 4 (UNI) While progress has been made in response to the plague outbreak in Madagascar, and the number of suspected new cases continues to decline, the World Health Organisation (WHO) has said that sustaining operations through the remainder of the plague season would be critical as there was still a risk of potential further spread of the disease.

Hepatitis

Hepatitis C, a liver disease caused by the hepatitis C virus

Kolkata, Nov 1 (UNI) Hepatitis C is a liver disease caused by the hepatitis C virus: the virus can cause both acute and chronic hepatitis, ranging in severity from a mild illness lasting a few weeks to a serious, lifelong illness.

As

As India stares at breast cancer epidemic, CURA launches robotic device for early detection

Chennai, Oct 31 (UNI) India was staring at a breast cancer epidemic and breast screening was virtually non-existent in India as one in 28 women get breast cancer and one in two die due to late detection, making survival one of the lowest in the world.

Solar eclipse 2017: North America will witness total solar eclipse

Solar eclipse 2017: North America will witness total solar eclipse

New York, Aug 21 (UNI) Today, all of North America will witness a total solar eclipse for the first time in 99 years, where the Moon will pass in front of the Sun, casting darkness across swathes of the Earth's surface - with up to 14 states shrouded in complete blackout.

Nano-particle fertilizer could lead to new 'green revolution'

Nano-particle fertilizer could lead to new 'green revolution'

New Delhi, Jan 26 (UNI) Sri Lankan scientists report having developed a simple way to make a benign, more efficient fertilizer – described as nano-particle fertilizer - that could contribute to a second food revolution across the globe.

Broken pebbles offer clues to Palaeolithic funeral rituals

Broken pebbles offer clues to Palaeolithic funeral rituals

New Delhi, Feb 9 (UNI) Humans may have ritualistically "killed" objects to remove their symbolic power, some 5,000 years earlier than previously thought, a new international study of marine pebble tools from an Upper Palaeolithic burial site in Italy suggests.

image